3 / 4
allied
academies
September 16-17, 2019 | Paris, France
Dementia and Alzheimer's Disease
13
th
World Congress on
Page 10
Journal of Clinical Psychiatry and Cognitive Psychology | Volume: 03
Azza A Ali
Al-Azhar University, Egypt
Reduction of Alzheimer's disease prevalence and progression using
multi-target therapeutic strategies
Prevalence of Alzheimer’s disease and Risk Factors
:
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by progressive and irreversible nerve cell death
throughout the brain including cerebral cortex, basal forebrain
and hippocampus thus, leading to memory loss and cognitive
impairment. It represents a pressing worldwide health
problem with major socioeconomic burden. The disease is
ultimately fatal and cell loss progress finally to a kinetic - mute
state. Mutation in genes which increase production of amyloid
β-peptides as well as which promote amyloid deposition,
neurotoxicity, oxidative stress, neurofibrillary tangle
formation, and increasing brain inflammation are reported to
be associatedwith the disease. Alzheimer’s disease progresses
gradually, brain shrinks dramatically over time but still there is
a lack of data about its progression. Scientists hope to model
stages for AD for more prediction of the disease progression,
expectation of its symptoms and to enhance the power to
find real treatment. Major attention has been paid to AD risk
factors especially modifiable ones as heavy smoking, excessive
alcohol drinking and low education as well as cognitive and
physical inactivity. History of depression and stress has been
also suggested as possible risk factors, in addition to several
environmental agents as dietary and malnutrition factors,
metals and pesticides as well as brain injuries. Diagnosis
mainly based on clinical assessment; however lab tests and
neuroimaging are used to exclude other disorders.
Multi-target Therapeutic Strategies
: For the complexity
involved in the mechanism of AD progression consequently,
multi-target therapeutic strategies are a must for providing
symptomatic and disease modifying benefits. Lifestyle
and healthy aging through reducing stress and increasing
cognitive engagement, physical activities, healthy food as
well as dietary supplementation of natural antioxidants,
vitamins, polyphenols, and zinc in combined treatments
showed marked protective effects rather than individual
treatments. The deleterious effect of stress on the brain can
be also counteracted by using both epigallocatechin-3-gallate
(EGCG) and diazepam. In experimental AD models, multi-
target therapeutic strategies showed promising results and
provided protection especially in the presence of different risk
factors as stress, isolation and protein malnutrition. Moreover,
the impact of EGCG, cocoa, pomegranate, coenzyme Q10,
wheat grass, propolis and vinpocetine either each alone or
in combination can greatly enhance the protective power of
physical and mental activity. On the other hand, there are
many challenges to developing vaccines that help to prevent
the disease in the early stages, which should be efficacious
regardless of patient immune status.
Speaker Biography
Azza A Ali has completed her PhD specialized in Pharmacology and
Toxicology from Faculty of Pharmacy, Cairo University, Egypt. She
developed research line of behavioral pharmacology in Egypt and
participated as Advisory Board Member of the Arab Association for
Pharmacy Development and its conference (AIPC 2019). She is member of
many scientific societies as (AAPS) and Alzheimer's Association (ISTAART).
She is also an Editorial Board Member of many international Journals as
Brain Disorder & Therapy, Acta Psychopathologica, EC Pharmacology and
Toxicology as well as Organizing Committee Member and Chairperson at
many international Conferences as the International Conference on Brain
Disorders & Dementia Care, Canada (2017) and International Conference
on Parkinson's Disease & Movement Disorders, USA (2017, 2018). She
published more than 60 papers in reputed journals, supervised and
discussed more than 90 PhD and MSc thesis and actively participated
by workshop, oral and posters presentations at many international
conferences especially on Dementia and Parkinson's disease and in the
Alzheimer's Association International Conference (AAIC 2016, 2017). She
has many appreciation certificates and certificate of best presentation
award at 19th International Conference on Environmental Pollution
and Pollution Control, London, UK (ICEPPC 2017). Now she is a Head of
Pharmacology and Toxicology Department andMember of the Committee
for the Promotion of Professors at Al-Azhar University, Egypt.
e:
azzamoro@gmail.com